HOME >> BIOLOGY >> NEWS
Biomedicines presents promising results from phase II trials of omega interferon for the treatment of hepatitis C

tectable in blood despite treatment with alpha interferon. Within 48 hours of the initiation of treatment with omega interferon, HCV RNA fell sharply in all patients, and in some to undetectable levels.

Chief Executive Officer Dr. Mark Moran said, "We are pleased with these results. We believe they also support our new drug delivery efforts with this drug. In collaboration with ALZA, we are also putting omega interferon into the implantable DUROS delivery system. With DUROS, we hope to be able to deliver omega interferon for months with a single administration.

Hepatitis C infection can lead to severe impairment of liver function, liver fibrosis, and liver cancer. According to the U.S. Center for Disease Control, HCV infects nearly 3 million people in the United States, and the World Health Organization estimates 170 million people are infected worldwide. Many infected persons are unaware of the infection. The spread of HCV infection has reached epidemic proportions, as some experts believe that without substantial improvements in treatment, the death toll from HCV infection will surpass that from HIV.


'"/>

Contact: Emily Katz
e.katz@noonanrusso.com
415-677-4455
Noonan/Russo Communications
12-Nov-2001


Page: 1 2

Related biology news :

1. DFG presents the 2004 MAK and BAT value lists
2. VIB presents its annual results at BIO2004 in San Francisco
3. Steroid-coated DNA represents new approach to gene delivery
4. ASH presents advocacy awards to Sen. Dianne Feinstein and Claude Lenfant, M.D.
5. DFG presents the new MAK and BAT Value List 2003
6. Center for Health Law and Policy presents program on bioterrorism measures and civil liberties
7. Agriculture presents common ground for rural, urban people
8. UPCI presents study on estrogenic activity of medicinal botanicals
9. UPCI presents study on dendritic cells in prostate cancer
10. UPCI presents study on discovery of protein that suppresses dendritic cells
11. USF presents new research on hyperlipidemic children

Post Your Comments:
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
Cached News: